Zentalis Pharmaceuticals, Inc. (ZNTL) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 8 Buy, 4 Hold.
The consensus price target is $2.00, representing a downside of 61.4% from the current price $5.19.
Analysts estimate Earnings Per Share (EPS) of $-2.46 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.33 vs est $-2.46 (beat +5.4%). 2025: actual $-1.91 vs est $-1.82 (missed -4.7%). Analyst accuracy: 95%.
ZNTL Stock — 12-Month Price Forecast
$2.00
▼ -61.43% Downside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Zentalis Pharmaceuticals, Inc., the price target is $2.00.
The average price target represents a -61.43% change from the last price of $5.19.
ZNTL Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Zentalis Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ZNTL
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.33
vs Est –$2.46
▲ 5.7% off
2025
Actual –$1.91
vs Est –$1.82
▼ 4.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ZNTL
60%
Analyst Accuracy
Fair
1 year compared
Actual vs Estimate
2024
Actual $0.067B
vs Est $0.041B
▲ 39.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
